Protection by Recombinant Newcastle Disease Viruses (NDV) Expressing the Glycoprotein (G) of Avian Metapneumovirus (aMPV) Subtype A or B against Challenge with Virulent NDV and aMPV

Qingzhong Yu, J. Roth, Haixia Hu, C. Estevez, Wei Zhao, L. Zsak
{"title":"Protection by Recombinant Newcastle Disease Viruses (NDV) Expressing the Glycoprotein (G) of Avian Metapneumovirus (aMPV) Subtype A or B against Challenge with Virulent NDV and aMPV","authors":"Qingzhong Yu, J. Roth, Haixia Hu, C. Estevez, Wei Zhao, L. Zsak","doi":"10.4236/WJV.2013.34018","DOIUrl":null,"url":null,"abstract":"Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candi-dates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous patho-genic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Ex-pression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"疫苗(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/WJV.2013.34018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candi-dates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous patho-genic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Ex-pression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.
表达A或B亚型禽偏肺病毒(aMPV)糖蛋白(G)的重组新城疫病毒(NDV)对新城疫病毒和aMPV攻击的保护作用
禽偏肺病毒(aMPV)和新城疫病毒(NDV)是在世界范围内引起禽类严重呼吸道疾病的具有威胁性的禽类病原体。疫苗接种与严格的生物安全措施相结合,一直是在实地控制这些疾病的建议。在本研究中,我们利用反向遗传学技术生成了以NDV LaSota疫苗株为基础的重组病毒,表达aMPV的糖蛋白(G), A或B亚型。这些重组病毒rLS/aMPV-A G和rLS/aMPV-B G在细胞培养中进行了表征,并在火鸡中作为二价下一代疫苗进行了评估。结果表明,与亲本LaSota病毒相比,这些重组候选疫苗在体内略有减毒,但在体外保持相似的生长动力学、细胞病变效应和病毒滴度。用免疫荧光法检测重组病毒感染细胞中aMPV - G蛋白的表达。接种rLS/aMPV- a G或rLS/aMPV- b G的火鸡对速度性NDV、CA02菌株的攻击具有完全保护作用,对同源致病性aMPV的攻击具有部分保护作用。这些结果表明,LaSota重组病毒是一种安全有效的疫苗载体,单独表达G蛋白不足以提供对aMPV-A或-B感染的充分保护。其他aMPV- a或-B病毒免疫原性蛋白单独或与G蛋白联合表达可能是诱导对aMPV疾病更强和更具保护性的免疫所必需的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
95
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信